自体免疫疾病治疗市场（按治疗类型、疾病类型、给药途径、治疗用途和最终用户划分）—2025-2032 年全球预测

预计到 2032 年，自体免疫疾病治疗市场将成长至 3,963.2 亿美元，复合年增长率为 7.96%。

主要市场统计数据
基准年2024年	2146.5亿美元
预计2025年	2311.5亿美元
预测年份：2032年	3963.2亿美元
复合年增长率（%）	7.96%

简洁的策略介绍，概述自体免疫疗法的临床挑战、商业性现实和相关人员协调

自体免疫治疗领域的特点是科学进步日新月异、监管环境复杂多变以及付款人预期不断变化，所有这些都影响着开发人员和投资者的策略选择。在这种环境下，一份简洁、将临床需求与商业性现实相结合的介绍，对于准备优先考虑产品线、分配资金以及与外部合作伙伴合作的经营团队至关重要。

本节概述了尚未满足的临床需求、精准生技药品和小分子药物的加速发展作用，以及与製造、低温运输物流和真实世界证据生成相关的运营挑战，为本文奠定了基础。本部分也强调了临床试验设计与长期价值创造之间的相互关係，并强调了与关键相关人员（包括临床医生、付款人和专业药房）进行早期合作的重要性。过渡性洞察重点介绍了近期创新可能与系统性限制因素相交的地方，为后续更深入的分析提供了实践基础。

科学、商业性和营运创新将如何融合，重塑自体免疫疾病治疗的临床策略和商业化路径

科学、技术和政策的变革性转变正在重新定义自体免疫疾病的诊断、治疗和管理方式，其影响波及整个价值链。生物治疗方法的进步、标靶小分子化学型的改进以及精准免疫调节方法的日益成熟，使得治疗策略更加明确地专注于改变疾病进展并实现持久缓解，而非仅仅控制症状。

同时，诊断技术的进步和生物标记主导的患者细分正在重塑临床试验队列，并加速自适应试验设计的发展。这种科学转变伴随着商业和商业性转型，包括开发商之间垂直整合的加强、製造和分销环节对战略伙伴关係关係的更大依赖，以及对数位化医疗辅助设备在提高用药依从性和监测安全性方面的日益增长的期望。这些变化迫使我们重新评估传统的商业化策略，并制定将临床差异化与可扩展製造和支付方证据要求相结合的整合策略。

评估不断变化的关税政策将如何影响自体免疫疗法供应链的弹性、製造地决策和筹资策略

美国将于2025年生效的新关税及相关贸易调整将对自体免疫治疗供应链、成本结构和产业计画产生多方面的影响。这些措施不仅会影响上游的原料药成分和生物製药材料的采购，还会影响下游的最终组装、填充和封口操作以及低温运输物流的地点决策。因此，企业正在重新评估筹资策略，以保持供应的连续性，同时降低进口成本上升的风险。

为了应对这种情况，许多相关人员正在推行近岸外包和区域化策略，以减少运输时间和监管摩擦，从而导致临床材料和商业库存的前置作业时间发生变化。委託製造製造商和经销商正在重新协商业务条款，以适应营运复杂性并确保服务水准的连续性。从策略角度来看，这些动态凸显了供应链弹性、多元化供应商网路以及将关税敏感性分析纳入监管提交时间表和临床开发预算的情境规划的重要性。最终，积极调整采购和製造布局的组织将更有能力维护患者的用药管道并保护治疗利润。

将治疗方式、适应症、给药途径、治疗意图和护理环境与开发和商业化需求联繫起来的全面細項分析

细緻的细分框架揭示了治疗方式、适应症、给药途径、治疗意图和最终用户环境如何影响开发重点和商业化策略。治疗类别涵盖多种模式，包括生物製药（如抗高血糖药、融合蛋白、基因疗法和单株抗体），以及细胞激素抑制剂、免疫调节剂、免疫抑制剂、非类固醇消炎剂、磷酸二酯酶抑制剂、皮质类固醇和小分子（包括JAK抑制剂）。每个类别的开发挑战、监管证据预期和製造考量都会影响临床时间和价值叙述。

疾病类型包括发炎性肠道疾病、红斑性狼疮、多发性硬化症、牛皮癣、类风湿性关节炎和第 1 型糖尿病。这种适应症的分布导致终点选择、试验持续时间和患者招募复杂性的异质性。给药途径主要分为注射疗法和口服疗法，注射疗法又分为肌肉注射、静脉注射和皮下注射。这些因素直接影响病患偏好、依从性模式和上市时所需的支援服务类型。治疗应用目标各不相同，包括改变疾病进展、调节免疫系统、控制疼痛和减轻炎症，每个目标都需要量身定制的临床方案和差异化的通讯。最终使用者包括门诊手术中心、医院和研究机构，这些环境决定了采购流程、处方定位和上市后证据收集的速度。整合这些细分维度使开发人员能够优先考虑与内部能力和外部访问一致的适应症和模式，同时使付款人和提供者能够更好地预测哪些治疗方法在个人医疗保健环境中提供最引人注目的价值提案。

区域策略对美洲、中东和非洲以及亚太地区不同管理体制、付款人模式和临床实践模式的影响

区域动态对于策略规划至关重要，因为不同地区的监管要求、付款人架构和临床实践模式差异巨大。美洲地区高度重视基于价值的报销途径、针对突破性疗法的加速监管项目，以及影响上市顺序和签约策略的庞大专业药房网络和一体化配送网络。这种环境有利于强有力的真实世界证据项目以及与付款人的早期合作，以确保药物的可及性和报销结果。

在欧洲、中东和非洲，市场进入方式多种多样，涉及不同程度的深入评估和针对特定国家的价格谈判，因此必须与卫生技术评估预期和当地临床指南保持一致。在该地区，能够明显抵消成本并带来长期效益的治疗方法往往更受青睐。在亚太地区，医疗保健体系发达的国家正迅速采用创新治疗方法，而其他面临公共预算限制的国家则正在采用分级准入策略。在这些市场中，弹性价格设定模式、与当地製造商的合作以及量身定制的临床开发计划可以加速治疗方法的采用。在所有地区，跨境监管协调工作和不断发展的数位基础设施将继续影响临床开发和商业化的策略选择。

透过结合科学创新、製造管理和证据产生能力，实现差异化的关键竞争和伙伴关係动态

领先研发公司、受託製造和服务供应商之间的竞争动态正日益受到策略联盟、垂直整合和定向收购的影响，这些倡议有助于提升生产规模和科研能力。拥有深厚生技药品专业知识和单株抗体、融合蛋白和基因治疗药物专有平台的公司正在透过将临床差异化与生产控制相结合来追求差异化定位，从而降低上市时间风险并增强品质保证。同时，规模较小、更敏捷的创新者正在利用伙伴关係关係来推进专用分子和利基适应症的开发，通常专注于伴随诊断和患者分层。

能够证明低温运输可靠性、灵活生产能力和合规性的契约製造和物流供应商，正成为寻求最大限度减少供应中断的开发商事实上的推广合作伙伴。此外，投资于强有力的真实世界证据生成和患者支持项目的组织，能够增强其与付款人和医疗保健提供者的谈判地位。这些策略倡议有利于那些能够将科学新颖性和付款人相关证据产生相结合的公司，从而为那些能够协调端到端开发和商业化路径的公司提供竞争优势。

可行的策略建议，以协调临床开发、供应链弹性和市场准备，从而加速患者获取药物并获得商业性成功

产业领导者应优先考虑一系列切实可行的措施，以解决临床差异化、供应链韧性和市场进入准备等问题。首先，应将早期临床开发与付款方证据要求相协调，积极与监管机构沟通，并降低关键试验设计和终点选择的风险。投资生物标记主导的患者分层和自适应测试方法可以缩短开发週期并增强价值檔案。其次，应实现供应商网路多元化，并考虑建立区域製造和策略伙伴关係，以降低关税和物流波动的影响。

第三，制定全面的打入市场策略，将临床效益与营运支援服务（例如病患援助、依从性计画和数位健康工具）结合，从而改善疗效并降低总护理成本。第四，与製造外包、分销合作伙伴和临床研究机构建立有针对性的合作伙伴关係，以确保在关键曲折点具备能力和专业知识。最后，将真实世界证据计画纳入开发路径，以支持跨区域系统的报销讨论。透过对这些行动进行排序并将其与明确的里程碑联繫起来，领导者可以降低执行风险并加快患者获得药物的速度。

一种透明、多方法的研究调查方法，结合专家访谈、监管分析、科学文献综述和供应链情境评估

本研究采用多种方法，结合定性专家访谈、监管和政策分析以及同行评审的科学文献综合分析，为策略决策建立了强有力的依证。主要的定性资讯是透过与临床研究人员、供应链高管、市场准入专家和付款人代表进行结构化访谈而获得的。

二次分析仔细审查了监管指南、临床试验註册和科学出版物，以检验特定治疗模式的开发路径和安全性。供应炼和关税影响评估是基于贸易流量数据和物流基准，并结合基于情境的敏感度检查来识别弱点。调查方法和资料来源的透明度有助于可重复性和有针对性的后续分析。

结论性观点将临床前景与营运要求以及市场进入先决条件相结合，以实现对患者产生有意义的影响

总而言之，自体免疫治疗领域正处于曲折点，科学突破必须与营运规范和成熟的市场进入策略结合。先进生技药品、标靶小分子药物和精准医疗方法的融合为改变疾病发展轨迹提供了重要机会，但要实现这一潜力，需要在临床证据生成、生产可靠性和支付方参与等方面开展合作。

投资于韧性供应链、生物标记赋能开发以及一体化商业支援服务的领导者，将最有能力将治疗前景转化为永续的患者效益。随着监管和贸易格局的演变，持续的情境规划和积极的相关人员参与将成为区分哪些专案能够实现广泛应用，哪些专案面临长期应用障碍的关键。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 针对 B 细胞和 T 细胞交互作用的双特异性抗体在狼疮治疗中的出现
• 基于 CRISPR 的基因编辑疗法推动类风湿性关节炎的个人化治疗
• 扩大JAK抑制剂和生物製药组合以增强干癣治疗的疗效
• 以微生物组为重点的治疗方法调节发炎性肠道疾病的肠道免疫途径
• 真实世界证据平台的成长支持加速自体免疫药物的核准
• 实施数位健康解决方案，监测患者在自体免疫疾病治疗中的依从性和结果

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章自体免疫疾病治疗市场（依治疗类型）

• 抗高血糖药物
• 生物製药
  • 融合蛋白
  • 基因治疗
  • 单株抗体
• 细胞激素抑制剂
• 免疫调节药物
• 免疫抑制剂
• 非类固醇消炎剂（NSAID）
• 磷酸二酯酶抑制剂
• 小分子
  • 皮质类固醇
  • JAK抑制剂

第九章自体免疫疾病治疗市场（依疾病类型）

• 发炎性肠道疾病
• 红斑狼疮
• 多发性硬化症
• 银屑病
• 类风湿性关节炎
• 1型糖尿病

第10章自体免疫疾病药物市场（依给药途径）

• 注射
  • 肌肉注射
  • 静脉
  • 皮下
• 口服

第11章自体免疫疾病药物市场（依治疗应用）

• 疾病进展的变化
• 免疫系统调节
• 疼痛管理
• 减少炎症

第 12 章自体免疫疾病治疗市场（按最终用户）

• 门诊手术中心
• 医院
• 研究机构

第十三章自体免疫疾病治疗市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章自体免疫疾病药物市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国自体免疫疾病治疗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exagen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • UCB SA
  • Werfen SA

The Autoimmune Disease Therapeutics Market is projected to grow by USD 396.32 billion at a CAGR of 7.96% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 214.65 billion
Estimated Year [2025]	USD 231.15 billion
Forecast Year [2032]	USD 396.32 billion
CAGR (%)	7.96%

A concise strategic introduction framing clinical imperatives, commercial realities, and stakeholder alignment across the autoimmune therapeutics landscape

The autoimmune therapeutics landscape is characterized by rapid scientific progress, complex regulatory pathways, and evolving payer expectations that together shape strategic choices for developers and investors. In this environment, a concise introduction that harmonizes the clinical imperatives with commercial realities is essential for executive teams preparing to prioritize pipelines, allocate capital, and engage external partners.

This section sets the stage by outlining prevailing clinical unmet needs, the accelerating role of precision biologics and small molecule agents, and the operational challenges associated with manufacturing, cold chain logistics, and real-world evidence generation. It emphasizes the interplay between clinical trial design and long-term value creation, and it underscores the importance of early alignment with key stakeholders, including clinicians, payers, and specialty pharmacies. Transitional insights highlight where near-term innovations are likely to intersect with systemic constraints, providing a pragmatic foundation for the deeper analyses that follow

How scientific, commercial, and operational innovations converge to reshape clinical strategies and commercialization pathways in autoimmune disease treatment

Transformative shifts across science, technology, and policy are redefining how autoimmune diseases are diagnosed, treated, and managed, with implications that reverberate across the entire value chain. Advances in biologic modalities, improvements in targeted small molecule chemotypes, and maturation of precision immunomodulatory approaches are enabling therapeutic strategies that focus more explicitly on altering disease progression and achieving durable remission rather than merely managing symptoms.

Concurrently, diagnostic improvements and biomarker-driven patient segmentation are reshaping clinical trial cohorts and accelerating adaptive trial designs. These scientific shifts are complemented by commercial and operational transformations, including increased vertical integration among developers, greater reliance on strategic partnerships for manufacturing and distribution, and elevated expectations for digital health adjuncts that improve adherence and monitor safety. Together, these changes necessitate a re-evaluation of traditional commercialization playbooks and call for integrated strategies that align clinical differentiation with scalable manufacturing and payer evidence requirements

Assessing how evolving tariff policies influence supply chain resilience, manufacturing footprint decisions, and procurement strategies for autoimmune therapies

The introduction of new tariff measures and related trade adjustments in the United States in 2025 exerts multifaceted effects across supply chains, cost structures, and operational planning for autoimmune therapeutics. These measures influence upstream procurement of active pharmaceutical ingredients and biologic raw materials, as well as downstream decisions related to where to site final assembly, fill-finish operations, and cold chain logistics. As a result, companies are recalibrating sourcing strategies to mitigate exposure to elevated import costs while preserving supply continuity.

In response, many stakeholders are pursuing near-shoring and regionalization strategies to reduce transit times and regulatory friction, which in turn changes lead times for clinical supplies and commercial inventory. Contract manufacturers and distributors are renegotiating terms to absorb operational complexity and to ensure service level continuity. From a strategic perspective, these dynamics emphasize the importance of supply chain resilience, diversified supplier networks, and scenario planning that integrates tariff sensitivity analyses into regulatory submission timelines and clinical development budgets. Ultimately, organizations that proactively adapt their sourcing and manufacturing footprints will be better positioned to maintain patient access and to protect therapeutic margins

Comprehensive segmentation analysis that links modality, indication, administration route, therapeutic intent, and care setting to development and commercialization imperatives

A nuanced segmentation framework reveals how therapeutic modality, disease indication, administration route, therapeutic intent, and end-user environment jointly inform development priorities and commercialization tactics. Therapeutic types encompass a diverse set of modalities including Antihyperglycemics, Biologics such as Fusion Proteins, Gene Therapy, and Monoclonal Antibodies, Cytokine Inhibitors, Immunomodulators, Immunosuppressants, Nonsteroidal Anti-Inflammatory Drugs, Phosphodiesterase Inhibitors, and Small Molecules which further include Corticosteroids and JAK Inhibitors. Each class carries distinct development challenges, regulatory evidence expectations, and manufacturing considerations that influence time-to-clinic and value narratives.

Disease types range across Inflammatory Bowel Disease, Lupus Erythematosus, Multiple Sclerosis, Psoriasis, Rheumatoid Arthritis, and Type 1 Diabetes, and this distribution of indications drives heterogeneity in endpoint selection, trial duration, and patient recruitment complexity. Route of administration considerations split primarily between Injectable and Oral therapies, with injectable delivery further differentiated by intramuscular, intravenous, and subcutaneous approaches; these factors have direct implications for patient preference, adherence patterns, and the types of support services required at launch. Therapeutic application objectives span disease progression alteration, immune system modulation, pain management, and reduction of inflammation, each demanding tailored clinical programs and differentiated messaging. End-user contexts include ambulatory surgical centers, hospitals, and research institutes, and these settings dictate procurement processes, formulary positioning, and the cadence of post-market evidence collection. By synthesizing these segmentation dimensions, developers can prioritize indications and modalities that align with internal capabilities and external access realities, while payers and providers can better anticipate which therapeutic profiles will offer the most compelling value propositions in distinct care settings

Regional strategic implications tied to divergent regulatory regimes, payer models, and clinical practice patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics are critical to strategic planning because regulatory requirements, payer architectures, and clinical practice patterns diverge substantially across geographies. In the Americas, there is a concentrated emphasis on value-based reimbursement pathways, accelerated regulatory programs for breakthrough therapies, and an extensive network of specialty pharmacies and integrated delivery networks that influence launch sequencing and contracting strategies. This environment rewards robust real-world evidence programs and early payer engagement to secure access and reimbursement outcomes.

Europe, Middle East & Africa presents a mosaic of market access approaches, with varying degrees of centralized assessment and country-specific pricing negotiations; here, alignment with health technology assessment expectations and local clinical guidelines is essential. The region often favors therapeutic approaches that demonstrate clear cost-offsets and long-term benefits. Asia-Pacific markets exhibit rapid adoption of innovative therapies in certain high-capacity health systems, while other countries within the region are characterized by constrained public budgets and tiered access strategies. For these markets, flexible pricing models, partnerships with local manufacturers, and tailored clinical development plans can accelerate uptake. Across all regions, cross-border regulatory harmonization efforts and evolving digital infrastructure will continue to influence strategic choices for clinical development and commercialization

Key competitive and partnership dynamics that deliver differentiation through combined scientific innovation, manufacturing control, and evidence generation capabilities

Competitive dynamics among lead developers, contract manufacturing organizations, and service providers are increasingly shaped by strategic collaborations, vertical integration, and targeted acquisitions that unlock manufacturing scale and scientific capabilities. Companies with deep biologics expertise and proprietary platforms for monoclonal antibodies, fusion proteins, and gene therapies are pursuing differentiated positioning by coupling clinical differentiation with manufacturing control, thereby reducing time-to-market risk and enhancing quality assurance. At the same time, smaller, nimble innovators are leveraging partnerships to advance specialized molecules and niche indications, often focusing on companion diagnostics and patient stratification.

Contract manufacturing and logistics providers that can demonstrate cold chain reliability, flexible capacity, and regulatory compliance are becoming de facto extension partners for developers seeking to minimize supply disruptions. Additionally, organizations that invest in robust real-world evidence generation and patient support programs enhance their negotiating posture with payers and providers. These strategic moves collectively favor entities that can align scientific novelty with operational excellence and payer-relevant evidence generation, creating a competitive advantage for those able to orchestrate end-to-end development and commercialization pathways

Actionable strategic recommendations that align clinical development, supply chain resilience, and market access preparations to accelerate patient access and commercial success

Industry leaders should prioritize a set of pragmatic, actionable steps that address clinical differentiation, supply chain resilience, and market access readiness. First, align early clinical development with payer evidence requirements and engage with regulatory authorities proactively to de-risk pivotal trial design and endpoint selection. Investing in biomarker-driven patient stratification and adaptive trial methodologies can shorten development cycles and strengthen value dossiers. Second, diversify supplier networks and consider regionalized manufacturing or strategic partnerships to mitigate tariff and logistics volatility while maintaining quality compliance and reliable supply for clinical and commercial phases.

Third, design integrated go-to-market strategies that couple clinical benefits with operational support services such as patient assistance, adherence programs, and digital health tools that improve outcomes and reduce total cost of care. Fourth, pursue deliberate collaborations with contract manufacturers, distribution partners, and clinical research organizations to secure capacity and specialized capabilities at critical inflection points. Finally, embed real-world evidence planning into development pathways to support reimbursement discussions across diverse regional systems. By sequencing these actions and tying them to clear milestones, leaders can reduce execution risk and accelerate patient access

Transparent multi-method research methodology combining expert interviews, regulatory analysis, scientific literature review, and supply chain scenario assessments

This research integrates a multi-method approach that combines qualitative expert interviews, regulatory and policy analysis, and synthesis of peer-reviewed scientific literature to produce a robust evidence base for strategic decision-making. Primary qualitative inputs were obtained through structured interviews with clinical investigators, supply chain executives, market access specialists, and payer representatives, enabling triangulation of perspectives across the development and commercialization continuum.

Secondary analysis consisted of a careful review of regulatory guidance, clinical trial registries, and scientific publications to validate modality-specific development pathways and safety profiles. Supply chain and tariff impact assessments were constructed using trade flow data and logistics benchmarks, together with scenario-based sensitivity checks to identify points of vulnerability. Throughout the methodology, cross-validation exercises ensured that conclusions were grounded in observable trends and expert judgment rather than speculation, and transparency around data sources and assumptions supports reproducibility and targeted follow-up analyses

Concluding perspective that synthesizes clinical promise with operational imperatives and market access prerequisites for meaningful patient impact

In conclusion, the autoimmune therapeutics arena is at an inflection point where scientific breakthroughs must be matched with disciplined operational execution and sophisticated market access strategies. The convergence of advanced biologics, targeted small molecules, and precision medicine approaches presents substantial opportunity to alter disease trajectories, but realizing that potential requires alignment across clinical evidence generation, manufacturing reliability, and payer engagement.

Leaders that invest in resilient supply chains, biomarker-enabled development, and integrated commercial support services will be best positioned to transform therapeutic promise into sustainable patient impact. As regulatory and trade landscapes evolve, continuous scenario planning and proactive stakeholder alignment will serve as the differentiating factors between programs that achieve broad access and those that face protracted adoption hurdles

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Emergence of bispecific antibodies targeting B cell and T cell interactions in lupus treatment
• 5.2. CRISPR-based gene editing therapeutics advancing personalized treatment for rheumatoid arthritis
• 5.3. Expansion of JAK inhibitor combinations with biologics to enhance efficacy in psoriasis management
• 5.4. Microbiome-focused therapies modulating gut immune pathways in inflammatory bowel disease
• 5.5. Growth of real-world evidence platforms supporting accelerated approval for autoimmune drugs
• 5.6. Adoption of digital health solutions to monitor patient adherence and outcomes in autoimmune care

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Autoimmune Disease Therapeutics Market, by Therapeutic Types

• 8.1. Antihyperglycemics
• 8.2. Biologics
  • 8.2.1. Fusion Proteins
  • 8.2.2. Gene Therapy
  • 8.2.3. Monoclonal Antibodies
• 8.3. Cytokine Inhibitors
• 8.4. Immunomodulators
• 8.5. Immunosuppressants
• 8.6. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• 8.7. Phosphodiesterase Inhibitors
• 8.8. Small Molecules
  • 8.8.1. Corticosteroids
  • 8.8.2. JAK Inhibitors

9. Autoimmune Disease Therapeutics Market, by Disease Type

• 9.1. Inflammatory Bowel Disease
• 9.2. Lupus Erythematosus
• 9.3. Multiple Sclerosis
• 9.4. Psoriasis
• 9.5. Rheumatoid Arthritis
• 9.6. Type 1 Diabetes

10. Autoimmune Disease Therapeutics Market, by Route of Administration

• 10.1. Injectable
  • 10.1.1. Intramuscular
  • 10.1.2. Intravenous
  • 10.1.3. Subcutaneous
• 10.2. Oral

11. Autoimmune Disease Therapeutics Market, by Therapeutic Application

• 11.1. Disease Progression Alteration
• 11.2. Immune System Modulation
• 11.3. Pain Management
• 11.4. Reduction of Inflammation

12. Autoimmune Disease Therapeutics Market, by End-User

• 12.1. Ambulatory Surgical Centers
• 12.2. Hospitals
• 12.3. Research Institutes

13. Autoimmune Disease Therapeutics Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Autoimmune Disease Therapeutics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Autoimmune Disease Therapeutics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Abbott Laboratories
  • 16.3.2. AbbVie Inc.
  • 16.3.3. Amgen Inc.
  • 16.3.4. AstraZeneca PLC
  • 16.3.5. Beckman Coulter, Inc.
  • 16.3.6. Bio-Rad Laboratories, Inc.
  • 16.3.7. BioAgilytix Labs, LLC
  • 16.3.8. bioMerieux S.A.
  • 16.3.9. Bristol-Myers Squibb Company
  • 16.3.10. Eli Lilly and Company
  • 16.3.11. Exagen, Inc.
  • 16.3.12. F. Hoffmann-La Roche Ltd.
  • 16.3.13. GlaxoSmithKline PLC
  • 16.3.14. Johnson & Johnson Services, Inc.
  • 16.3.15. Lupin Limited
  • 16.3.16. Merck & Co., Inc.
  • 16.3.17. Novartis AG
  • 16.3.18. Pfizer, Inc.
  • 16.3.19. Sanofi S.A.
  • 16.3.20. Siemens Healthineers AG
  • 16.3.21. Thermo Fisher Scientific Inc.
  • 16.3.22. Trinity Biotech PLC
  • 16.3.23. UCB S.A.
  • 16.3.24. Werfen S.A.